Q1 2027 Earnings Call November 5, 2026 10:30 AM ESTCompany ParticipantsPatrick Roberts - Director of Corporate ...

When a tool produces that first draft, the main change is in where the hours are spent; improvements in the quality of the ...

Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further ...

First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor ...

ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Brisk Enrollment in Asia-PacificNext ALPHA3 Clinical Update Anticipated in Mid-2027, with Trial ...

Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, ...

WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- . (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utiliz ...

The following slide deck was published by The New York Times Company in conjunction with their 2026 Q3 earnings call.

Tangram Therapeutics ("Tangram"), a company committed to unlocking transformative RNAi medicines for meaningful patient ...

Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its ...

TGM-148 silences Protein Z-dependent Protease Inhibitor (ZPI), a natural regulator of coagulation. It is designed to combine robust hemostatic efficacy with low thrombotic risk and infrequent ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...